StudyFinder

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

572 Study Matches

A Phase 1/2, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Efficacy of BMN 331, an Adeno-Associated Virus (AAV) Vector-Mediated Gene Transfer of Human SERPING1, in Subjects with Hereditary Angioedema (HAE) due to Human C1 Esterase Inhibitor (C1-INH) Deficiency

BMN 331 is an experimental drug that is being tested for the treatment of patients with HAE. This study is the first time BMN 331, which is a gene therapy, is being used in humans. BMN 331 is given only once during this research study and it is given as an infusion. The purpose of this study is to find out what effects, good and/or bad, the Study Drug has on you and your HAE.

You will have a total of 68 in person visits over 68 months where there will be blood drawn and other lab tests. You will have to travel to an off site location to receive the drug once and travel will be paid for by the sponsor of the trial.

Yes
 

Timothy Craig
Hunter Smith - at hsmith16@pennstatehealth.psu.edu
Medicine: Pulmonary, Allergy and Critical Care (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05121376
STUDY00019539
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Male or Female, 18 years of age or older
Have a diagnosis of Hereditary Angioedema type I or type II
Willing to abstain from alcohol consumption for 52 weeks after the infusion
Females of childbearing potential must be willing to use contraception

Exclusion Criteria:
Evidence of active or chronic infection, including Covid-19, or any immunosuppressive disorder
Active cancer, autoimmune, hematologic, cardiac, or renal diseases which require regular treatment
Long term use of attenuated androgens
using immunosuppressants including corticosteroids
Infectious Diseases & Immune System, Allergies
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Assessment of nocturnal hypoventilation in amyotrophic lateral sclerosis

The overall goals of this study are to identify how measurement of carbon dioxide during sleep can improve recognition of respiratory distress in neuromuscular disease and thus improve timely access to respiratory therapies which prolong survival. Subjects in this study will participate for up to one year, during which their carbon dioxide levels will be measured in clinic and in their homes during sleep.

Subjects in this study will participate for up to one year, during which their carbon dioxide levels will be measured using deviced attached to the skin while in clinic and in their homes during sleep. Subjects will also complete surveys at the time of clinic visits.

50

Yes
 

Andrew Geronimo
Andrew Geronimo - at ageronimo@pennstatehealth.psu.edu
Neurosurgery (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00017603
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of amyotrophic lateral sclerosis
18 years of age or older.
Plan to be followed up in person in the Hershey ALS Clinic for the next 12 months.
Experiencing early respiratory change.
Able to perform or have assistance performing home CO2 measurements.

Exclusion Criteria:
In hospice or in active transition to hospice
Use of any type of non-invasive ventilation, except in the case of CPAP for obstructive sleep apnea, or have a tracheostomy
Use of diaphragm pacer
Pre-existing pulmonary disease requiring supplemental oxygen for any portion of the day or night
Neurology
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Strengths, Outcomes, Adversity, and Resilience in College-Aged Childhood Cancer Survivors: The PSU SOAR Study

The purpose of this study is to analyze the strengths, outcomes, adversity, and resilience, as indicated by self-reported experiences in college students who may or may not be childhood cancer survivors. We are asking college students aged 18-23 years attending 4 year universities in the United States to report on their childhood health experiences and their current mental, physical, and social well being during college using a confidential survey. We plan to recruit students who have or have not had a childhood history of cancer and will also ask questions about their demographic information and health habits.

The participants will be asked to complete a confidential online survey that will take 10-15 minutes to complete.

Participants are eligible to earn a $75 Amazon gift card through a random drawing that they can choose to enter after submitting their survey responses

No
 

Laura Klein
Nikolette Nolte - at nmn5225@psu.edu or 484-268-6550
Biobehavioral Health (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00019071
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Aged 18-23 years
College student attending 4 year university
English as primary language

Exclusion Criteria:
Younger than 18 years or older than 23 years
Not attending a 4 year university
Does not have English as primary language
Mental & Behavioral Health, Cancer
Not applicable
I'm interested
Share via email

Epigenetics and Bipolar Disorder: The Role of Reelin in Bipolar Disorder

This study is designed to compare biological markers of mood in participants with bipolar disorder to individuals without bipolar disorder. Participants will answer questions, give blood, and undergo a clinical interview. This study is a 1 time appointment lasting no longer than 1.5 hours and participants will be compensated $50.

One in person visit with interviews, questionnaires, and a blood sample.

$50

Yes
 

Erika Saunders
Zachary Nitsch - at znitsch@pennstatehealth.psu.edu or 717-531-0003, ext=329699
Psychiatry and Behavioral Health (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00006080
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Healthy Control
18 Years or Older
No diagnosis of psychiatric disorder

Exclusion Criteria:
Diagnosis of autism spectrum disorder, substance use disorders, schizophrenia or other psychotic disorder
Pregnancy
Investigator discretion regarding ability to participate in the study
Mental & Behavioral Health
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

One Penn State : Connecting a Learning Community of Geographically Diverse Students

The community of remote learners is on the rise. With the trends of application and skill based knowledge, more and more people are migrating to the learn while you work paradigm. People value flexibility and comfort increasingly. Penn State is one of the few Universities propagating the cause of spreading knowledge via all modalities. The 33,302 students spread across its 19 commonwealth campuses are further a testimony to the prevalent trends. It is important that all these students receive an integrated and cohesive student experience. This also covers the need for the students to feel a sense of social belongingness. The work will focus on bringing together the Penn State community to achieve the true essence of it’s chant WeAre!

No
 

Sanjana Gautam
Sanjana Gautam - at sqg5699@psu.edu
Division of Graduate Studies (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00013646
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must be 18 years of age or older
Must be a student of Penn State

Exclusion Criteria:
Most not be younger than 18 years of age
Education
I'm interested
Share via email

Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) (PSCI# 21-207) (NRG-HN009)

The purpose of this study is to compare two usual treatment approaches to your head and neck cancer: high-dose cisplatin given every 3 weeks with radiation to low-dose cisplatin given weekly with radiation. The first part of this study will help the study doctors find out if the low-dose cisplatin approach is better tolerated than the high-dose cisplatin approach. To decide if it is better, the study doctors will be looking to see if there are fewer side effects for patients who receive low-dose cisplatin weekly compared to patients who receive high-dose cisplatin every 3 weeks. The second part of this study will also help the study doctors find out if the low-dose cisplatin approach will extend your life by at least the same amount of time as the high-dose cisplatin approach. There will be 464 people in the first part of the study. If the study goes on to the second part, there will be 786 additional people. Overall, there will be a total of up to 1250 people taking part in this study.

he first part of this study will help the study doctors find out if the low-dose cisplatin approach is better tolerated than the high-dose cisplatin approach. To decide if it is better, the study doctors will be looking to see if there are fewer side effects for patients who receive low-dose cisplatin weekly compared to patients who receive high-dose cisplatin every 3 weeks.The second part of this study will also help the study doctors find out if the low-dose cisplatin approach will extend your life by at least the same amount of time as the high-dose cisplatin approach.There will be 464 people in the first part of the study. If the study goes on to the second part, there will be 786 additional people. Overall, there will be a total of up to 1250 people taking part in this study.

Yes
 

Sean Mahase
PSCI-CTO@pennstatehealth.psu.edu
Radiation Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05050162
SITE00001120
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Pathologically (histologically or cytologically) proven diagnosis of SCCHN of the oropharynx, larynx, hypopharynx, or p16-positive unknown primary prior to registration
Age ≥ 18
Zubrod (ECOG) performance status of 0-1 within 14 days prior to registration
Adequate hematologic function within 30 days prior to registration
Adequate renal function within 30 days prior to registration defined as calculated creatinine clearance (CrCl) ≥ 50 mL/min by the Cockcroft-Gault formula

Exclusion Criteria:
Patients with oral cavity cancer, nasopharynx cancer, or p16-negative cancer of unknown primary (CUP);
Definitive clinical or radiologic evidence of distant metastatic disease
Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable, however, any prior exposure to cisplatin is excluded
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Pregnancy and individuals unwilling to discontinue nursing
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

User experience with smart devices

This study investigates users’ experience with smart devices. This study makes further implications for designing more user-friendly devices for better user experience. We aim to make such contributions by answering these questions:1.How do users interact with smart devices?2.What challenges do users face when using smart devices?3.What strategies do users apply to adapt themselves to smart devices?4.What service do smart device producers provide for users to get a better user experience?5.When does user experience break down when interacting with smart devices?The study methods are social media data analysis, interview, survey, and focus group.

Yes
 

Yubo Kou
Yao Lyu - at yml5549@psu.edu
Information Sciences and Technology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00014519
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years or elder
all genders included
have prior experience with smart devices

Exclusion Criteria:
younger than 18 years old
all vulnerable populations, such as pregnant women, cognitive impaired adults, and prisoners.
no prior experience with smart device
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

In Alexa, we Trust. Or do we ? : A Case Study of Privacy Policies of Amazon's Intelligent Voice Assistant

Trying to understand how humans alter their behavior when presented with new information regarding privacy rules.

No
 

Sanjana Gautam
Sanjana Gautam - at sqg5699@psu.edu or 814-867-5787
Division of Graduate Studies (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00014700
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must be 18 years of age or older
Must own a smart home device

Exclusion Criteria:
Most not be younger than 18 years of age
I'm interested
Share via email

Translational Studies on Electronic Cigarette-derived Oxidants and their Long-term Cardiopulmonary Effects

This is a pilot study on the impact of switching from cigarettes to Electronic Cigarettes on disease-related clinical symptoms and biomarkers of harm in smokers with preexisting COPD

You will be asked to reduce your cigarette smoking and use study-provided e-cigarettes for 3 months. You will be asked to attend 2 in-person visits at the Hershey Medical Center and participate in 4 telephone visits. Throughout the study you will be asked to complete questionnaires, have heart rate, blood pressure and pulse oximetry taken, electrocardiograms (ECGs), height and weight measured, provide medical history, perform pulmonary function tests, complete a 6-minute walk, have your exhaled carbon monoxide measured, provide urine specimen and have blood drawn.

Yes
 

Rebecca Bascom
Timothy Sheehan - at tsheehan@pennstatehealth.psu.edu or 717-531-2925
Medicine: Pulmonary, Allergy and Critical Care (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05239793
STUDY00015514
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Ages 21-74
mild-moderate COPD
current smoker

Exclusion Criteria:
actively changing smoking behavior
current use of other tobacco products
allergic to vegetable glycerin and/or propylene glycol
chronic drug and/or alcohol abuse
Smoking, Vaping, Nicotine and Tobacco, Addiction & Substance Abuse, Lung Disease & Asthma
Approved device(s)
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor (PSCI# 21-039)

The purpose of the dose-escalation part is to evaluate GEN1046 in subjects with solid malignant tumors to determine the maximum tolerated dose (MTD) or maximum administered dose and/or the recommended phase 2 dose (RP2D). The purpose of the expansion part is the further evaluate the safety, tolerability, PK and antitumor activity of the selected dose(s) in select solid tumors.

The participants will be required to follow the trial doctor's instructions, have tests and checks done as part of the trial, inform the trial doctor of any changes in how they are feeling, be open and honest about their health history, inform the study team of all concomitant medications, and inform the trial doctor if you decide not to participate in the trial anymore.

Yes
 

Patrick Ma
psci-cto@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05117242
STUDY00019590
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Subject must be at least 18 years of age
Subject has histologically or cytologically confirmed diagnosis of stage 4 NSCLC with at least 1 prior line of systemic therapy containing an anti-PD-1/PD-L1 monoclonal antibody (mAb)
Subject must have tumor PD-L1 expression of tumor proportion score (TPS) >= 1%
Subject must have measurable disease per RECIST v1.1
Subject must have Eastern Cooperative Oncology Group (ECOG) PS <= 1

Exclusion Criteria:
Subject has documentation of known EGFR, ROS1 or ALK mutations or gene rearrangements
Subject has been exposed to prior treatment with docetaxel for NSCLC
Subject has been exposed to prior treatment with a 4-1BB (CD137) targeted agent, any type of antitumor vaccine or autologous cell immunotherapy
Subject has been exposed to treatment with an anti-cancer agent within 28 days prior to GEN1046 administration
Subject discontinued treatment due to disease progression within the first 6 weeks of a CPI-containing treatment
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

EA2197: Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial (PSCI# 21-111)

The purpose of this study is to compare the usual treatment (surgery plus chemotherapy after) to using chemotherapy both before and after surgery. Receiving gemcitabine/cisplatin chemotherapy both before and after surgery could extend your life and prevent your cancer from returning. But, it could also cause side effects, which are described in the risks section below. This study will help the study doctors find out if this different approach is better than the usual approach. To decide if it is better, the study doctors will look to see if the chemotherapy increases the time to disease recurrence and if it increases a patient’s overall survival compared to the usual approach given both before and after surgery.

We are asking you to take part in a research study. This study has public funding from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) in the United States Department of Health and Human Services. We do research studies to try to answer questions about how to prevent, diagnose, and treat diseases like cancer. We are asking you to take part in this research study because you have recently been diagnosed with gallbladder cancer that was found after your gallbladder was removed during surgery.

Yes
 

Rushin Brahmbhatt
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Surgery: General Surgery (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04559139
SITE00001045
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Patient must be = 18 years of age.
Patient must have an ECOG performance status of 0-1.
Patient must have undergone initial cholecystectomy within 12 weeks prior to randomization
Patient must have histologically-confirmed T2 or T3 gallbladder cancer discovered incidentally at the time of or following routine cholecystectomy for presumed benign disease

Exclusion Criteria:
Patient must not have any evidence of metastatic disease or inoperable loco-regional disease based on high-quality, preoperative, cross-sectional imaging (CT or MRI) of the chest, abdomen, and pelvis (C/A/P) obtained within 6 weeks prior to randomization
Women must not be pregnant or breast feeding due to the potential harm to unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used.
No radiographic evidence of distant disease (M1 disease)
No radiographic evidence of tumor invasion into multiple extrahepatic organs (T4 disease)
No radiographic evidence of distant lymph node involvement (celiac, para-aortic, para-caval lymph nodes)
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

User Mobility and Graph Learning in Virtual Reality

This study investigates how the interaction affects how well 3D graphs are understood and remembered in virtual reality, and how individual differences in spatial ability affect and interact with memory and understanding.

Yes
 

Alexander Klippel
Mark Simpson - at mbs278@psu.edu
Geography (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00007004
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Penn State Affiliation

Exclusion Criteria:
Under age 18
Education
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Psychological and Biological Determinants of Eating Disorder Pathology in Endurance and Aesthetic Athletes

The purpose of this study is to investigate psychobiological factors that impact the development and manifestation of eating disorder (ED) pathology in elite male and female athletes before and during their competitive season.

The purpose of this voluntary research study is to assess how changes in stress, cognitive flexibility, response inhibition, and reward delay predict the trajectory of eating disorder behaviors and associated side effects of energy deficiency from the off-season compared to the competitive season. Your participation in this study will last approximately the duration of one season of your sport, specifically 4-weeks of data collection prior to season commencement (baseline), 4-weeks of data collection during peak competition season, and 4-weeks of data collection during off-season. The total time spent in the lab will be approximately 10-14 hours. Procedures will occur three times and measurements will be taken twice following baseline measures (once during the peak competition season, once during off-season), if you agree to do so.

$50

Yes
 

Mary Jane De Souza
Emily Lundstrom - at eal259@psu.edu or 814-863-4488
Kinesiology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00018984
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 18-25 years
A member of a Penn State NCAA Division 1 Sports team, or Penn State affiliated competitive club team, or competitive community sport team
Exercising without any training modifications that reduce training participation.
non-smoker
No serious of chronic health conditions

Exclusion Criteria:
BMI >32kg/m2 or <16.5 kg/m2
Currently a smoker or history of regular smoking (including nicotine products, e-cigarettes, vaping)
Medications influencing metabolic or endocrine factors (e.g., hormonal use in previous 6 months)
Medical instability or history of psychosis
Vasectomy (male) or Hysterectomy or oophorectomy (female)
Men's Health, Food & Nutrition, Women's Health
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Examining brain responses linked to emotion in individuals who smoke cigarettes

The goal of this study is to measure emotional and brain responses related to the motivation to smoke cigarettes. The study uses a method called functional magnetic resonance imaging, or fMRI, which is a research method for measuring activity in the brain. The study also involves measuring moment-to-moment changes in emotion by coding facial expressions. A primary goal of the project is to examine how changes in brain activity are related to changes in emotion over time. If successful, the project will help to demonstrate the usefulness of combining fMRI and facial coding to study cigarette smoking and other harmful behaviors.

There will be two in-person visits. Brain imaging scans (using functional magnetic resonance imaging) will be completed at one of these visits.

100

Yes
 

Stephen Wilson
Stephen Wilson - at sjw42@psu.edu
Psychology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
NCT04310735
STUDY00011266
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Between 21 and 55 years old
Must smoke cigarettes each day
Must be right handed
Must be fluent English speaker
Must be willing to abstain from smoking for 12 hours during the study

Exclusion Criteria:
Must not be actively trying to quit smoking
Must not currently have significant cardiovascular or respiratory disease
Must not be claustrophobic
Smoking, Vaping, Nicotine and Tobacco, Addiction & Substance Abuse, Cancer
Not applicable
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

The Sexual Relationships Study

The purpose of this study is to examine the sexual relationships among heterosexual female college students (ages 18-22) via Qualtrics (a web-based survey). Utilizing latent class analysis with a distal outcome, the proposed cross-sectional study seeks to do the following: Aim 1. Examine the heterogeneity in relationship quality among female college students. Research question 1: Is there a latent class structure that adequately represents the heterogeneity in relationship quality among female undergraduate students participating in penile-vaginal sex? If so, what are the types and their corresponding prevalence?Aim 2. Examine the association between relationship characteristics and latent class membership.Research question 2: Are relationship characteristics (partner type, relationship duration, exclusivity/monogamy, and frequency of sex) predictive of membership in latent classes of relationship quality?Aim 3. Examine the association between latent classes of relationship quality and condom use.Research question 3: Which identified latent class of relationship quality is significantly associated with condom use at last penile-vaginal sex?Please note that the indicators measuring relationship quality will include the following variables: 1) trust, 2) love, 3) passion, 4) commitment, 5) relationship satisfaction, 6) sexual satisfaction, 7) intimacy, and 8) decision-making dominance.

No
 

Jessica Salas
Jessica Salas-Brooks - at jis5940@psu.edu or 704-249-4252
Biobehavioral Health (UNIVERSITY PARK)
 

Female
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00006941
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Be enrolled at Pennsylvania State University (University Park Campus)
Be between the ages of 18-22 years
Be a female college student
Be sexually active with male partners in the previous 3 months

Exclusion Criteria:
Are not enrolled at Pennsylvania State University (University Park Campus)
Are under the age of 18 or over the age of 22.
Are not a female college student
Are not sexually active with male partners in the previous 3 months
Women's Health
I'm interested
Share via email

Observational Study for Pediatric Rheumatic Diseases: The CARRA Registry

The original Childhood Arthritis &amp; Rheumatology Research Alliance (CARRA) Registry was first established in 2010 to advance alliance infrastructure,facilitate expanded clinical and translational pediatric research, and transform the culture of pediatric rheumatology toward universal participation in research. Continuation of the CARRA Registry as described in the protocol attached to this IRB submission will support data collection onpatients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressingquestions about therapeutics used to treat pediatric rheumatic diseases, including examining safety questions. The Duke Clinical Research Institute (DCRI) is serving as the CARRA Clinicaland Data Coordinating Center (CDCC) for this protocol.

In addition to allowing the researchers to collect data on you from your medical record, we will ask you and your parents/caregivers to complete a short survey that takes about 15 minutes to completeThe research team will follow up every 6 months by reviewing your medical record and asking you and your parents/caregivers to complete a short survey that takes about 15 minutes to complete.If you agree to take part, you will be in the study for 10 or more years.

Yes
 

Timothy Hahn
Meredith Buckley - at mbuckley@pennstatehealth.psu.edu
Pediatrics: General Pediatrics (HERSHEY)
 

All
Younger than 18 years old
This study is NOT accepting healthy volunteers
STUDY00008987
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Onset of rheumatic disease prior to age 16 years for Juvenile Idiopathic Arthritis
Onset prior to age 19 years for all other rheumatic diseases
Willing to participate in a registry you will be followed during your treatment and have information about you disease and treatment collected.

Exclusion Criteria:
More than 21 years of age.
Arthritis & Rheumatic Diseases
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

A Phase Ib/II Study of APG-115 as a Monotherapy or in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors

Part 1 (Phase Ib): To determine the safety and ability for subjects to tolerate APG-115 when combined with pembrolizumab, as well as the maximum tolerated dose in subjects with metastatic melanomas or solid tumors.Part 2 (Phase II): To determine the overall response rate of APG-115 when combined with pembrolizumab in the treatment of patients with unresectable or metastatic melanomas. To assess APG-115 as a monotherapy in patients with unresectable or metastatic melanomas and MPNST cohorts only.

If you are eligible and agree to receive the study drug combination, you will need to come to the study site at various times to have procedures done. These procedures may include collection of vital signs, blood andurine samples, electrocardiogram, physical exam, tumor biopsy, imagingscans, and x-ray. At each visit, you will be asked about your current medicines, including over-the-counter medications, and about any symptoms or side effects you might be having. You will receive the study drug orally on Days 1, 3, 5, 7, 9, 11, 13 of every 21-day cycle. Pembrolizumab is given as a 30-minute intravenous (IV – through a needle into a vein) infusion on Day 1 of every 21-day cycle.

Yes
 

Joseph Drabick
Irina Geier - at igeier@pennstatehealth.psu.edu
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03611868
STUDY00014555
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Male or non-pregnant, non-lactating female patients age ≥18 years on day of signing the informed consent
Histologically confirmed, unresectable or metastatic melanoma, and refractory or relapse after PD1 antibody treatment and ineligible for other standard of care therapy
ECOG Performance scale of 0-2
Life expectancy of equal to or greater than 3 months
Adequate bone marrow and organ functionAdequate

Exclusion Criteria:
Any prior systemic MDM2-p53 inhibitor treatment Received chemotherapy within 21 days (42 days for nitrosoureas or mitomycin C) prior to first dose.
Prior loco-regional treatment with intralesional therapy (e.g. talimogene laherparepvec) for unresectable or metastatic melanoma in the last 6 months prior to start of study treatment.
Received hormonal and biologic (<1 half-lives), small molecule targeted therapies or other anti-cancer therapy within 21 days prior to first dose Radiation or surgery within 14 days of study entry, thoracic radiation within 28 days prior to first dose.
Has known active central nervous (CNS) metastases and/or carcinomatous meningitis. Or has neurologic instability per clinical evaluation due to tumor involvement of the CNS.
Requirement for corticosteroid treatment, with the exception of megestrol, local use of steroid: i.e.: topical corticosteroids, inhaled corticosteroids for reactive airway disease, ophthalmic, intraarticular, and intranasal steroids.
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Using ERPs and eye-tracking to study language learning and processing in adult learners.

In an increasingly global environment, both within the US and abroad, the ability to rapidly gain native-like linguistic competence is a critical asset. The ability to use an L2 in a way that is both expected and recognized by its native speakers is important both to the broad public, and to specific sectors, such as military personnel, that must develop native-like competence in a foreign language in a limited amount of time. The studies conducted under this IRB protocol will examine how learners/speakers of a second language acquire and process multi-word units (e.g., carry a business; run a store) in their second language, and how knowledge from the first language might influence the learning and processing of multi-word units in a second language.

Participants will complete a number of simple tasks on a computer in English and/or in Spanish (depending on language background).

$12/hour

Yes
 

Manuel Pulido
Manuel Pulido - at mfp149@psu.edu
Spanish, Italian and Portuguese (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00011115
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Be a native speaker of English or Spanish
Not fluent in other languages
No history of neurological or language disorders
Normal or normal-to-corrected vision
Right-handed

Exclusion Criteria:
Native speaker of a language different from English or Spanish
Older than 45 years old
Left-handed or ambidextrous
A history of neurological disorders or language disorders
Education, Language & Linguistics
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Elucidating the Necessary Active Components of Training (ENACT) Study

This study will examine the effects of different brain games on cognitive and everyday activities in middle-aged and older adults. Participants will play either 20 or 40 hours of ENACT brain games on a study provided laptop. They will also complete daily surveys on a study-provided mobile phone for the duration of the study. These surveys will take approximately 5-6 minutes to complete per day. The study will last either 6 or 9 months depending on the brain game training time. The study will be done remotely from the comfort of home using study-provided mobile devices. Participants are compensated for their time.

Participants will play either 20 or 40 hours of ENACT brain games on a study provided laptop. They will also complete daily surveys on a study-provided mobile phone for the duration of the study. These surveys will take approximately 5-6 minutes to complete per day. The study will last either 6 or 9 months depending on the brain game training time. The study will be done remotely from the comfort of home using study-provided mobile devices.

$230

No
 

Martin Sliwinski
Jordan Solt - at jvs6276@psu.edu or 814-865-4773
Human Development and Family Studies (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00010760
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 55-85
Strong English writing and comprehension
Willing to participate for 5 to 9 months

Exclusion Criteria:
Involved in brain training, such as Lumocity or BrainHQ
History of dementia or Alzheimer's Disease
Use of video games for more than 2 hours/week over the previous 2 years
Prevention, Mental & Behavioral Health
I'm interested
Share via email

Walking through the forests of the future: Using data-driven iVR to visualize forests under climate change

We used a combination of ecological modeling, procedural modeling, and virtual reality to provide an embodied experience of “walking through the forests of the future”. This study will provide empirical evidence of the effectiveness of this immersive experience based on users’ feedbacks on different kinds of tools we developed.

Yes
 

Jiawei Huang
Jiawei Huang - at jzh87@psu.edu or 734-355-5327
Geography (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00011770
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
forestry or climate science related majors (include but not limited to agricultural sciences, environmental resources management, forest ecosystem management, plant science, ecology, biology, meteorology and atmospheric science)
undergraduate or graduate students at Penn State University who are older than 18.
participants should be healthy (without contagious disease)

Exclusion Criteria:
people under 18
people who are cognitively impaired
people who have contagious disease
Education, Language & Linguistics
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

PSCI 21-038 Phase Ib Study of Brigatinib Plus Bevacizumab in Patients with ALK-rearranged Non-Small Cell Lung Cancer (NSCLC)

Clinical trial on the treatment of persons who are diagnosed with Lung Cancer.

Participants in this study will undergo screening tests and procedures to determine whether you are eligible to participate with the research study. If you meet the requirements to participate with the study, you be given Brigatinib by mouth each day for 7 days. If you do not experience any intolerable side effects while taking Brigatinib, you will receive an increased dose starting on Day 8 and take Brigatinib continuously each day thereafter. Bevacizumab will be given intravenously (IV) on Day 8 in combination with Brigatinib. The first 28 days of treatment is called Cycle 1. Starting Cycle 2 and thereafter, one cycle will consist of 21 days. Bevacizumab will be given on Day 1 every 21 days starting Cycle 2. Participation is expected to last until your disease worsens or you decide you no longer want to participate in the study. There will be a follow-up visit within 30 days of treatment discontinuation. The study team will check in with you every three months after this final visit to see how you are doing.If you decide to take part, this is what will happen: Since we are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects in participants that have Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLS), not everyone who participates in this research study will receive the same dose of the study drug. The dose you get will depend on the number of participants who have been enrolled in the study before you and how well they have tolerated their doses. If you take part in this research study, you will be given a drug diary. You will be asked to document information in the drug diary about the study drug you are being asked to take.If you take part in this research, study you will be given a study calendar. Information about what to expect during and between study visits will be included in the study calendar.

Yes
 

Patrick Ma
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04227028
STUDY00018451
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
lung cancer

Exclusion Criteria:
other cancer in the last 3 years
major surgery in the last 30 days
heart attack or stroke in the last 6 months
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Insulitis, Inflammation, Dietary intake and Omega-3 Biostatus of Youth with Partial Remission of Type 1 Diabetes

Only 50% of patients with type 1 diabetes (T1D) recover insulin secretion function after 3 months of initial diagnosis, and this phase is called partial remission (PR) of T1D, also called "Honeymoon phase". During this PR phase of T1D, patients recover the ability to secrete more than 50% of their insulin secretion function. This phase of PR typically lasts no longer than 6 or up to12 months, and has been frequently defined as requiring exogenous insulin below 0.5 units per kilogram per day, and hemoglobin A1C is typically below 7.5%. Most recently the use of a coefficient called IDAA1C ≤ 9 has became more accepted as the methodology to determine the development of partial clinical remission of T1D (honeymoon phase). Prior data published by the SEARCH study (national epidemiological study) showed that youth with prolonged honeymoon phase had higher intake of omega -3 fatty acids, vitamin D intake and leucine intake than those youth without prolonged honeymoon phase of T1D. Currently, there are not approved medications to prolong this phase of partial remission of type 1 diabetes, however inducing PR in youth with T1D could potentially decrease the risk of multi-organ damage caused by chronic severe hyperglycemia associated to the chronic hyperglycemia related to T1D.We aim to perform a case- multiple control study between youth with prolonged partial remission phase of T1D after one year of diagnosis, and compare these youths with multiple controls matched by age, gender, race, and puberty stage to study the potential protective factors associated to the development of prolonged partial remission of T1D.

Participants will be approached at their routine Pediatric diabetes clinic appointment. If participants agrees to be in the research, informed consent/assent will be reviewed and signed by all parties. Participant's parent/guardian will be asked to complete a questionnaire. The participant's glucose machine/insulin pump will be downloaded for study purposes. Participant will undergo a fingerstick and a blood draw to collect specific lab values as outlined in the consent.

$35.00

Yes
 

Lina Huerta-Saenz
Erica Miller - at emiller25@pennstatehealth.psu.edu or 717-531-5656
Pediatrics: Endocrinology (HERSHEY)
 

All
Younger than 18 years old
This study is NOT accepting healthy volunteers
STUDY00014114
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Type 1 diabetes diagnosis for more than one year
Age 1-17 years old, any gender
Attendance to the Pediatric diabetes clinic at Penn State Health in Hershey, PA
Most recent hemoglobin A1C below 7.5%

Exclusion Criteria:
Age older than 17 years old
History of seafood allergies and/or milk/dairy related allergies
Medical conditions (such as severe cerebral palsy, etc.) that could make patients unable to communicate with the study team
Existence of other autoimmune diseases in addition to T1D requiring regular treatment with immunosuppressive or anti-inflammatory treatment
Diagnosis of type 2 diabetes, monogenic diabetes (MODY), secondary diabetes, pregnancy, compromised kidney function, or liver diseases
Children's Health, Food & Nutrition, Diabetes & Hormones
I'm interested
Share via email
Show 3 locations

Study Locations

Hide all locations
Location Contacts
Carlisle, PA ,
Harrisburg, PA ,
Hershey, PA ,

Memory and Aging Study

This research is being done to find out more about changes in the brain as we age and to determine if MRI, genetic (DNA) variations, and neuropsychological tests can be used to evaluate memory loss and cognitive impairment.

Yes
 

Prasanna Karunanayaka
Lauren Spreen - at lspreen@pennstatehealth.psu.edu
Radiology (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
PRAMS040153EP
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of Alzheimer's disease
Diagnosis of Mild Cognitive Impariment
Normal Controls-Cognitively normal functioning

Exclusion Criteria:
Neurological disease (e.g., stroke, tumor, Parkinson's disease, etc.)
Psychiatric disorder (e.g., bi-polar, schizophrenia, etc.)
History of chemotherapy
Presence of a cold or viral infection
Presence of a pacemaker, aneurysm clips, or any metal in body
Neurology
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

A Pre-Post Study of the Use of Transcutaneous Electrical Nerve Stimulation Unit in the Management of Endometriosis Pain

The purpose of this study is see if Transcutaneous Electrical Nerve Stimulator (TENS) units help decrease endometriosis flare pain. Participants will complete surveys, record pain, medication use and bleeding in an online diary during endometriosis flare ups for 3 months without using the TENS unit. After the first 3 month period of time, a TENS unit will be given to participants to wear and again, record pain, medication use and bleeding in the online diary during endometriosis flare ups for and additional 3 months while using the TENS unit.

There will be one in person enrollment visit, involving being consented and completion of 2 surveys. The first 3 months, the "baseline period" will include filling out pain scores online on days of endometriosis flare without TENS unit use. The next 3 months, the "treatment period" will include filling out pain scores online on days of endometriosis flare with TENS unit. At end of study completion of 2 surveys.

Yes
 

Kristin Riley
Patricia Rawa - at prawa@pennstatehealth.psu.edu
Obstetrics and Gynecology (HERSHEY)
 

Female
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05348005
STUDY00019024
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Women aged 18 to 45 years, inclusive,
Surgical diagnosis of endometriosis, visualized and/or pathology confirmed
Having monthly endometriosis pain flares on average
Has never used a TENS unit before for endometriosis pain flares
Must be greater than 12 weeks post-op for abdominal/pelvic surgery

Exclusion Criteria:
Has an implantable device (e.g. pacemaker, etc.)
Has a cardiac arrhythmia
Has open skin sores over area of TENS placement
Not planning to have surgery or hormonal medication changes during the study
Pregnant
Pain Management, Women's Health
Prefer not to display
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

PSCI 22-082 Tropion-Breast03

This is an investigational drug study comparing the Investigational treatment with treatments called capecitabine and pembrolizumab as stand-alone treatment agents or in combination. Study participants will be required to attend all study visits, complete the tests and procedures, receive study treatment, and complete questionnaires.

Participants must attend all visits, receive study treatment, have blood drawn, complete questionnaires, have imaging scans done (ECG, ECHO or MUGA, CT, mammogram or breast MRI), keep a diary, have an eye exam, and provide a tumor sample.

Yes
 

Monali Vasekar
PSCI-CTO at PSCI-CTO@pennstatehealth.psu.edu or 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05629585
SITE00001344
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Participant must be ≥ 18 years at the time of screening.
Histologically confirmed invasive TNBC.
Residual invasive disease in the breast and/or axillary lymph node(s) at surgical resection following neoadjuvant therapy.
Completed at least 6 cycles of neoadjuvant therapy containing an anthracycline and/or a taxane with or without carboplatin, with or without pembrolizumab.14
No evidence of locoregional or distant relapse. Radiological scans before treatment are not required and should be obtained as per local institutional practice.

Exclusion Criteria:
Stage IV (metastatic) TNBC.
History of prior invasive breast cancer, or evidence of recurrent disease following preoperative therapy and surgery.
As judged by the investigator, any evidence of diseases (such as severe or uncontrolled systemic diseases, including history of allogeneic organ transplant and active bleeding diseases, ongoing or active infection,
History of another primary malignancy except for adequately resected basal cell carcinoma of the skin or squamous cell carcinoma of the skin, in situ disease that has undergone potentially curative therapy
Persistent toxicities caused by previous anticancer therapy, excluding alopecia, not yet improved to Grade ≤ 1 or baseline.
Cancer
Experimental drug compared to an approved drug
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

An Examination of Student-Mentor Relationships

This is a self-report survey and questionnaire study that examines whether members of marginalized groups are more motivated than members of dominant groups to give referent power to high status others in attempts to belonging.

No
 

Maria Sanchez
Maria Sanchez - at mfs5350@psu.edu
Psychology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00007731
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
All Genders
All races/ethincities
Participants between 18 and 25

Exclusion Criteria:
Participants YOUNGER than 18
Participants OLDER than 25
I'm interested
Share via email

Decision-Making in ADHD: An Evaluation of the Subjective Value of Rewards and Costs

Children with attention and behavior problems often need external rewards to motivate them to perform challenging tasks, but we don’t yet know much about how children weigh potential rewards and the effort required to obtain the rewards. This research is being done to find out how children with varying levels of ADHD symptoms value rewards and costs when making decisions about whether or not to perform a difficult task.

There will be one in-person visit. Children will complete two computerized cognitive tasks (thinking games), and will be able to earn prizes from the points they earn on these tasks. Parents will also be asked to complete a few questionnaires that should take about 25 minutes to finish. Children can earn up to $50 in compensation for completing the study.

$50

Yes
 

Dan Waschbusch
Hunter Weidlich - at abc@pennstatehealth.psu.edu or 717-531-0003, ext=285969
Psychiatry and Behavioral Health (HERSHEY)
 

All
Younger than 18 years old
This study is also accepting healthy volunteers
STUDY00018076
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Children ages 8 to 12 years old
Children with normal or corrected vision
Caregiver and child must be fluent in written and spoken English
Willing to stop stimulant medications, when appropriate, for research testing

Exclusion Criteria:
Children who are younger than 8 years of age and children who are older than 12 years of age.
Current or past diagnosis of autism spectrum disorder, schizophrenia or other psychotic disorders.
Current use of non-stimulant medication due to its extended washout period.
Physical disabilities that are incompatible with completing laboratory tasks such as hearing impairments, or visual impairments that cannot be corrected with visual aids (i.e., glasses, contacts).
Children's Health, Mental & Behavioral Health
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Examining Maternal Reward Responsiveness and the Intergenerational Risk for Depression

Children of depressed mothers are at high risk for developing depression, particularly as youth age into adolescence, yet relatively little is known about the mechanism underlying risk for depression in youth with depressed mothers. The present study examines maternal reward responsiveness, measured across neurophysiological, behavioral, and self-report measures as a marker of depression in mothers of adolescents. Associations between maternal reward responsiveness and parenting difficulties often associated with maternal depression, as well as adolescent functioning will be examined, to explore the clinical impact of maternal reward responsiveness on the intergenerational transmission of depression.

Yes
 

Dahlia Mukherjee
Sarah Shahriar - at sshahriar1@pennstatehealth.psu.edu or 717-531-0003, ext=285189
Psychiatry and Behavioral Health (HERSHEY)
 

All
All
This study is also accepting healthy volunteers
STUDY00009643
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Female adults 18 years and above with an adolescent child aged 13-16 years
Capacity for informed consent
Fluent in verbal and written English
Adolescent between the ages of 13 and 16 years (inclusive)

Exclusion Criteria:
Diagnosis of autism spectrum disorder, substance use disorders, schizophrenia or other psychotic disorder
Any hearing or visual impairments
Investigator discretion regarding ability to participate in the study
Children's Health, Mental & Behavioral Health, Women's Health
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

20-099, EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response

The purpose of this study is to test whether it is safe to eliminate additional chemotherapy after surgery in patients with HER2-positive breast cancer who have no remaining cancer at surgery, after receiving a single chemotherapy drug (for most patients, paclitaxel), with Herceptin (trastuzumab) and Perjeta (pertuzumab) for 12 weeks before surgery. The standard treatment for patients who have no remaining cancer at surgery is to receive additional chemotherapy after surgery. This study will test whether patients who receive no further chemotherapy after surgery have no higher chance of tumor recurrence than patients who have received additional chemotherapy after surgery.

The purpose of this study is to test whether it is safe to eliminate additional chemotherapy after surgery in patients with HER2-positive breast cancer who have no remaining cancer at surgery, after receiving a single chemotherapy drug (for most patients, paclitaxel), with Herceptin (trastuzumab) and Perjeta (pertuzumab) for 12 weeks before surgery. The standard treatment for patients who have no remaining cancer at surgery is to receive additional chemotherapy after surgery. This study will test whether patients who receive no further chemotherapy after surgery have no higher chance of tumor recurrence than patients who have received additional chemotherapy after surgery.

Yes
 

Cristina Truica
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04266249
SITE00000861
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Histologically confirmed HER2-positive primary invasive breast carcinoma
Patents must have a left ventricular ejection fraction (LVEF) within normal institutional parameters (or > 50%).

Exclusion Criteria:
Patient must not have a history of any prior (ipsilateral or contralateral) invasive breast cancer.
Patient must not have Stage IV (metastatic) breast cancer
Patient must not have T4 and/or N3 disease, including inflammatory breast cancer.
Patient must not have any prior treatment for the current breast cancer, including surgery, chemotherapy, hormonal therapy, radiation or experimental therapy.
Patient must not have a concurrent serious medical condition that would preclude completion of study therapy.
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

The role of middle temporal and frontoparietal areas in limb motor control

The goal of this research is to understand the role of motion-processing areas on limb motor control. We will be using behavioral studies and combining that with functional brain imaging, EEG, and non-invasive brain stimulation using transcranial magnetic stimulation (TMS). TMS has been used in thousands of studies and is a very safe method to understand brain function for eye hand coordination.

There will be three visits. Participants will under go brain scanning. They will perform eye-hand coordination tasks by grabbing a robotic manipulandum. During the eye-hand coordination tasks, participants' brain activity will be measured using electroencephalography (EEG) and muscle activity using surface electromyography (EMG). Researchers will also apply transcranial magnetic stimulation (TMS) to temporarily inhibit and excite different brain areas. TMS is a noninvasive procedure that uses magnetic fields to stimulate nerve cells

50

Yes
 

Tarkeshwar Singh
Tarkeshwar Singh - at tsingh@psu.edu or 814-865-7851
Kinesiology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00018993
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Participants should be between 18-50 years old
Participants should be right-hand dominant individuals
Participants should be able to sit upright in a chair for long periods (up to 2 and a half hours) with rest
Participants should be able to grasp and move objects with both hands
Participants should be able to lie still and perform behavioral tasks inside a magnetic scanner for up to 60 minutes

Exclusion Criteria:
History of neurological disorders (e.g., Seizures, Parkinson’s or Alzheimer’s disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Friedreich's ataxia, aneurism, brain tumor, epilepsy, traumatic brain injury, a concussion in the last five years)
Any history of musculoskeletal disorders (e.g., carpal tunnel syndrome, any form of arthritis, fibromyalgia, tendinitis, or previous injury or surgery to the bones or joints in your neck, upper back, arms or hands in the last six months)
Eye or vision problems (e.g., cataracts, glaucoma, a detached retina, or macular degeneration)
Individuals with metallic implants will be excluded from the study. The metallic implant will make participation in a magnetic scanner impossible
Medication that could make the participant drowsy or tired during the experiment
Neurology, Vision & Eyes
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,